Scroll Top

News & events

PRESS RELEASES

Gain Therapeutics

Gain Therapeutics side image

August 25, 2026

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

August 11, 2026

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

July 16, 2026

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

June 29, 2026

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

June 10, 2026

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

May 26, 2026

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

IN THE NEWS

July 31, 2026

Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s

https://podcast.labiotech.eu/1995493/episodes/19417648-gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinson-s

July 1, 2026

Parkinson’s pipeline pushes beyond dopamine

https://www.biocentury.com/article/659501/parkinson-s-pipeline-pushes-beyond-dopamine?utm_term=profiles.biocentury.com

June 30, 2026

Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com

https://in.investing.com/news/stock-market-news/gain-therapeutics-stock-surges-on-fda-clearance-for-parkinsons-drug-93CH-5475234

June 11, 2026

Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s

https://european-biotechnology.com/latest-news/scenic-biotech-joins-michael-j-fox-lrrk2-consortium-with-a-novel-lysosomal-bet-on-parkinsons/

June 10, 2026

Beyond amyloid and dopamine: emerging technologies reshaping neurology

https://www.labiotech.eu/in-depth/neurology-technology/

June 9, 2026

Bial drops pariceract after Phase IIb failure in GBA-associated Parkinson’s

https://european-biotechnology.com/latest-news/bial-drops-pariceract-after-phase-iib-failure-in-gba-associated-parkinsons/

EVENTS

June 12, 2026

H.C. Wainwright Fireside Chat with President and CEO Gene Mack

March 23, 2026

ROTH Fireside Chat with President and CEO Gene Mack

February 25, 2026

Oppenheimer Fireside Chat with President and CEO Gene Mack – 36th Annual Healthcare Life Sciences Conference

January 6, 2026

Parkinson’s Disease KOL Event: Understanding GCase Substrates in Parkinson’s Disease – Perspectives on Biomarkers and Disease Modification

October 13, 2025

Parkinson’s Disease KOL Event: Biomarkers, Clinical Endpoints, and the Path to Disease Modification

May 21, 2025

Citizens Life Sciences Conference Company Presentation